Flag of the European Union EU Clinical Trials Register Help

Clinical trials

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44043   clinical trials with a EudraCT protocol, of which   7319   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     

    < Back to search results

    Print Download

    Summary
    EudraCT Number:2021-005092-39
    Sponsor's Protocol Code Number:TA-8995-304
    National Competent Authority:Italy - Italian Medicines Agency
    Clinical Trial Type:EEA CTA
    Trial Status:Ongoing
    Date on which this record was first entered in the EudraCT database:2022-02-11
    Trial results
    Index
    A. PROTOCOL INFORMATION
    B. SPONSOR INFORMATION
    C. APPLICANT IDENTIFICATION
    D. IMP IDENTIFICATION
    D.8 INFORMATION ON PLACEBO
    E. GENERAL INFORMATION ON THE TRIAL
    F. POPULATION OF TRIAL SUBJECTS
    G. INVESTIGATOR NETWORKS TO BE INVOLVED IN THE TRIAL
    N. REVIEW BY THE COMPETENT AUTHORITY OR ETHICS COMMITTEE IN THE COUNTRY CONCERNED
    P. END OF TRIAL
    Expand All   Collapse All
    A. Protocol Information
    A.1Member State ConcernedItaly - Italian Medicines Agency
    A.2EudraCT number2021-005092-39
    A.3Full title of the trial
    Obicetrapib and Cardiovascular Outcomes: A Placebo-Controlled, Double- Blind, Randomized Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Who are Not Adequately Controlled Despite Maximally Tolerated Lipid-Modifying Therapies
    Obicetrapib ed esiti cardiovascolari: Studio di fase 3 randomizzato, in doppio cieco, controllato con placebo per valutare l’effetto di 10 mg di Obicetrapib in partecipanti affetti da malattia cardiovascolare aterosclerotica (ASCVD) non adeguatamente controllati nonostante le terapie modificanti i lipidi alla dose massima tollerata
    A.3.1Title of the trial for lay people, in easily understood, i.e. non-technical, language
    A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease (ASCVD) Whose Current Treatment with Lipid-Modifying Therapies is not Sufficiently Effective
    Studio di fase 3 controllato con placebo per valutare l’effetto di 10 mg di Obicetrapib in partecipanti affetti da malattia cardiovascolare aterosclerotica (ASCVD) in cui l'attuale trattamento con terapie modificanti i lipidi non è sufficientemente efficace
    A.3.2Name or abbreviated title of the trial where available
    Obicetrapib effect in Participants With Atherosclerotic Cardiovascular Disease (ASCVD)
    effetto di 10 mg di Obicetrapib in partecipanti affetti da malattia cardiovascolare aterosclerotica
    A.4.1Sponsor's protocol code numberTA-8995-304
    A.7Trial is part of a Paediatric Investigation Plan No
    A.8EMA Decision number of Paediatric Investigation Plan
    B. Sponsor Information
    B.Sponsor: 1
    B.1.1Name of SponsorNewAmsterdam Pharma B.V.
    B.1.3.4CountryNetherlands
    B.3.1 and B.3.2Status of the sponsorCommercial
    B.4 Source(s) of Monetary or Material Support for the clinical trial:
    B.4.1Name of organisation providing supportNewAmsterdam Pharma B.V.
    B.4.2CountryNetherlands
    B.5 Contact point designated by the sponsor for further information on the trial
    B.5.1Name of organisationNewAmsterdam Pharma B.V.
    B.5.2Functional name of contact pointClinical Operations
    B.5.3 Address:
    B.5.3.1Street AddressGooimeer 2-35
    B.5.3.2Town/ cityNaarden
    B.5.3.3Post code1411 DC
    B.5.3.4CountryNetherlands
    B.5.4Telephone number+31352062971
    B.5.5Fax number+31202400779
    B.5.6E-mailmarc.ditmarsch@newamsterdampharma.com
    D. IMP Identification
    D.IMP: 1
    D.1.2 and D.1.3IMP RoleTest
    D.2 Status of the IMP to be used in the clinical trial
    D.2.1IMP to be used in the trial has a marketing authorisation No
    D.2.5The IMP has been designated in this indication as an orphan drug in the Community No
    D.2.5.1Orphan drug designation number
    D.3 Description of the IMP
    D.3.1Product nameObicetrapib
    D.3.2Product code [TA-8995]
    D.3.4Pharmaceutical form Film-coated tablet
    D.3.4.1Specific paediatric formulation No
    D.3.7Routes of administration for this IMPOral use
    D.3.8 to D.3.10 IMP Identification Details (Active Substances)
    D.3.8INN - Proposed INNObicetrapib
    D.3.9.1CAS number 866399-89-5
    D.3.9.2Current sponsor codeTA-8995
    D.3.9.4EV Substance CodeSUB188624
    D.3.10 Strength
    D.3.10.1Concentration unit mg milligram(s)
    D.3.10.2Concentration typeequal
    D.3.10.3Concentration number10
    D.3.11 The IMP contains an:
    D.3.11.1Active substance of chemical origin Yes
    D.3.11.2Active substance of biological/ biotechnological origin (other than Advanced Therapy IMP (ATIMP) No
    The IMP is a:
    D.3.11.3Advanced Therapy IMP (ATIMP) No
    D.3.11.3.1Somatic cell therapy medicinal product Information not present in EudraCT
    D.3.11.3.2Gene therapy medical product Information not present in EudraCT
    D.3.11.3.3Tissue Engineered Product Information not present in EudraCT
    D.3.11.3.4Combination ATIMP (i.e. one involving a medical device) Information not present in EudraCT
    D.3.11.3.5Committee on Advanced therapies (CAT) has issued a classification for this product Information not present in EudraCT
    D.3.11.4Combination product that includes a device, but does not involve an Advanced Therapy No
    D.3.11.5Radiopharmaceutical medicinal product No
    D.3.11.6Immunological medicinal product (such as vaccine, allergen, immune serum) No
    D.3.11.7Plasma derived medicinal product No
    D.3.11.8Extractive medicinal product No
    D.3.11.9Recombinant medicinal product No
    D.3.11.10Medicinal product containing genetically modified organisms No
    D.3.11.11Herbal medicinal product No
    D.3.11.12Homeopathic medicinal product No
    D.3.11.13Another type of medicinal product No
    D.8 Information on Placebo
    D.8 Placebo: 1
    D.8.1Is a Placebo used in this Trial?Yes
    D.8.3Pharmaceutical form of the placeboFilm-coated tablet
    D.8.4Route of administration of the placeboOral use
    E. General Information on the Trial
    E.1 Medical condition or disease under investigation
    E.1.1Medical condition(s) being investigated
    atherosclerotic cardiovascular disease (ASCVD)
    Malattia cardiovascolare aterosclerotica (ASCVD)
    E.1.1.1Medical condition in easily understood language
    atherosclerotic heart and blood vessel disease (the narrowing of arteries from a buildup of plaque)
    Malattia aterosclerotica del cuore e dei vasi sanguigni (restringimento delle arterie in seguito a formazione di una placca).
    E.1.1.2Therapeutic area Diseases [C] - Cardiovascular Diseases [C14]
    MedDRA Classification
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 21.1
    E.1.2Level LLT
    E.1.2Classification code 10051615
    E.1.2Term Atherosclerotic cardiovascular disease
    E.1.2System Organ Class 100000004866
    E.1.2 Medical condition or disease under investigation
    E.1.2Version 20.0
    E.1.2Level LLT
    E.1.2Classification code 10076622
    E.1.2Term Atherosclerotic plaque
    E.1.2System Organ Class 100000004866
    E.1.3Condition being studied is a rare disease No
    E.2 Objective of the trial
    E.2.1Main objective of the trial
    To evaluate the effect of obicetrapib on the risk of major adverse cardiovascular events (MACE), including CV death, non-fatal MI, nonfatal stroke, or non-elective coronary revascularization.
    Valutare l’effetto di obicetrapib sul rischio di eventi avversi cardiovascolari maggiori (MACE), tra cui decesso CV, IM non fatale, ictus non fatale o rivascolarizzazione coronarica non elettiva.
    E.2.2Secondary objectives of the trial
    • CV death, non-fatal MI, or non-fatal stroke;
    • All-cause mortality, non-fatal MI, non-fatal stroke, or non-elective coronary revascularization;
    • Any individual component of the primary composite endpoint;
    • Total CV events;
    • New-onset diabetes mellitus (NODM);
    • Percent change in low-density lipoprotein cholesterol (LDL-C);
    • Percent change in non-high-density lipoprotein cholesterol (non-HDLC);
    • Percent change in apolipoprotein B (ApoB); and
    • Absolute change in glycosylated hemoglobin (HbA1c) in participants with diabetes mellitus and HbA1c =7% at Baseline.
    • decesso CV, IM non fatale o ictus non fatale;
    • mortalità per tutte le cause, IM non fatale, ictus non fatale o rivascolarizzazione coronarica non elettiva;
    • qualsiasi componente individuale dell’endpoint composito primario;
    • eventi CV totali;
    • diabete mellito di nuova insorgenza (NODM);
    • variazione percentuale del colesterolo legato alle lipoproteine a bassa densità (LDL-C);
    • variazione percentuale del colesterolo non legato alle lipoproteine ad alta densità (non-HDL-C);
    • variazione percentuale dell’apolipoproteina B (ApoB); e
    • variazione assoluta dell’emoglobina glicosilata (HbA1c) in partecipanti con diabete mellito e HbA1c =7% al basale.
    E.2.3Trial contains a sub-study No
    E.3Principal inclusion criteria
    - Men or women =18 years of age at Screening (Visit 1);
    - Have a history of ASCVD, defined by at least 1 of the following conditions:
    o Coronary artery disease
    o Cerebrovascular disease
    o Peripheral arterial disease
    - Are on maximally tolerated lipid-modifying therapy defined as follows:
    o A statin at a maximally tolerated stable dose;
    o Ezetimibe for at least 4 weeks prior to Screening (Visit 1);
    o Bempedoic acid for at least 4 weeks prior to Screening (Visit 1);
    o A PCSK9-targeted therapy for at least 3 stable doses prior to Screening (Visit 1);
    o A fibrate at a stable dose for at least 6 weeks prior to Screening (Visit 1) (with the exception of gemfibrozil, which is not allowed);
    and/or
    o Statin intolerant participants and participants using a statin at a maximally tolerated stable dose may be on any of the following or combinations of ezetimibe, bempedoic acid, a PCSK9-targeted therapy, or a fibrate as defined in the previous bullets.
    - Have a fasting serum LDL-C as follows:
    o Have a fasting serum LDL-C =80 mg/dL to <100 mg/dL with at least 1 of the following risk enhancers:
    - Recent MI (>3 and <12 months prior to Randomization);
    - Type 2 diabetes mellitus;
    - Fasting triglycerides (TG) >150 mg/dL (>1.7 mmol/L); and/or
    - Fasting HDL-C <40 mg/dL (<1.0 mmol/L).
    OR
    o Have a fasting serum LDL-C =100 mg/dL.
    - Have fasting TG <400 mg/dL (<4.52 mmol/L) at Screening (Visit 1);
    and
    - Have an estimated glomerular filtration rate (eGFR) =30 mL/min/1.73 m2 calculated using the Chronic Kidney Disease Epidemiology Collaboration equation at Screening (Visit 1).
    Other protocol-defined criteria apply.
    - Uomini o donne di età =18 anni allo Screening (Visita 1).
    - Anamnesi di ASCVD, definita da almeno 1 delle seguenti condizioni:
    o Cardiopatia coronarica:
    o Malattia cerebrovascolare:
    o Arteriopatia periferica:
    - In trattamento con terapia modificante i lipidi alla dose massima tollerata, definita come segue:
    o una statina a una dose stabile massima tollerata;
    o ezetimibe per almeno 4 settimane precedenti lo Screening (Visita 1);
    o acido bempedoico per almeno 4 settimane precedenti lo Screening (Visita 1);
    o una terapia mirata con PCSK9 per almeno 3 dosi stabili precedenti lo Screening (Visita 1);
    o un fibrato a una dose stabile per almeno 6 settimane precedenti lo Screening (Visita 1) (ad eccezione di gemfibrozil, che non è consentito); e/o
    o i/le partecipanti intolleranti alle statine e i partecipanti che utilizzano una statina a una dose stabile massima tollerata possono essere trattati/e con uno qualsiasi dei seguenti o con combinazioni di ezetimibe, acido bempedoico, una terapia mirata con PCSK9 o un fibrato, come definito nei punti precedenti.
    - Livello di LDL-C sierico a digiuno come segue:
    o Livello di LDL-C sierico a digiuno compreso tra =80 mg/dl e <100 mg/dl con almeno 1 dei seguenti potenziatori di rischio:
    ¿ IM recente (>3 e <12 mesi precedenti la Randomizzazione);
    ¿ diabete mellito di tipo 2;
    ¿ trigliceridi (TG) a digiuno >150 mg/dl (>1,7 mmol/l); e/o
    ¿ HDL-C a digiuno <40 mg/dl (<1,0 mmol/l).
    OPPURE
    o Livello di LDL-C sierico a digiuno =100 mg/dl.
    - Livelli di TG a digiuno <400 mg/dl (<4,52 mmol/l) allo Screening (Visita 1); e
    - Velocità di filtrazione glomerulare stimata (eGFR) =30 ml/min/1,73 m2, calcolata utilizzando l’equazione sviluppata dalla Chronic Kidney Disease Epidemiology Collaboration allo Screening (Visita 1).
    Si applicano altri criteri definiti da protocollo
    E.4Principal exclusion criteria
    1. Have current or any previous history of New York Heart Association class III or IV HF or left ventricular ejection fraction <30%;
    2. Have been hospitalized for HF within 5 years prior to Screening (Visit1);
    3. Have had any of the following clinical events within 3 months prior toScreening (Visit 1):
    o Non-fatal MI;
    o Non-fatal stroke;
    o Non-elective coronary revascularization; and/or
    o Hospitalization for unstable angina and/or chest pain;
    4. Have uncontrolled severe hypertension, defined as either systolicblood pressure =160 mmHg or diastolic blood pressure =100 mmHgprior to Randomization, taken as the average of triplicatemeasurements. One triplicate retest will be allowed during the same visit, at which point if the retest result is no longer exclusionary, the participant may be randomized;
    5. Have a formal diagnosis of homozygous familial hypercholesterolemia;
    6. Have active liver disease, defined as any known current infectious, neoplastic, or metabolic pathology of the liver; unexplained elevations in alanine aminotransferase (ALT) or aspartate aminotransferase (AST) >3 × upper limit of normal (ULN); or total bilirubin >2 × ULN at Screening (Visit 1);
    7. Have an HbA1c =10% at Screening (Visit 1);
    8. Have a thyroid-stimulating hormone >1.5 × ULN at Screening (Visit1);
    9. Have a creatine kinase >3 × ULN at Screening (Visit 1);
    Other protocol-defined criteria apply.
    1. Anamnesi attuale o pregressa di scompenso cardiaco di classe III o IV secondo la New York Heart Association o frazione di eiezione ventricolare sinistra <30%.
    2. Ricovero ospedaliero per insufficienza cardiaca (IC) nei 5 anni precedenti lo Screening (Visita 1).
    3. Manifestazione di uno qualsiasi dei seguenti eventi clinici nei 3 mesi precedenti lo Screening (Visita 1):
    o IM non fatale;
    o ictus non fatale;
    o rivascolarizzazione coronarica non elettiva; e/o
    o ricovero ospedaliero per angina instabile e/o dolore toracico.
    4. Ipertensione grave non controllata, definita come pressione arteriosa sistolica =160 mmHg o pressione arteriosa diastolica =100 mmHg prima della randomizzazione, misurata come media delle misurazioni in triplicato. Sarà consentita una ripetizione in triplicato del test durante la stessa visita; a quel punto, laddove il risultato della ripetizione del test non fosse più esclusorio, il/la partecipante potrà essere randomizzato/a.
    5. Diagnosi formale di ipercolesterolemia familiare omozigote.
    6. Malattia epatica attiva, definita come qualsiasi nota patologia epatica infettiva, neoplastica o metabolica in corso; aumenti inspiegabili dell’alanina aminotransferasi (ALT) o dell’aspartato aminotransferasi (AST) >3 volte il limite superiore dell’intervallo normale (ULN); oppure bilirubina totale >2 volte il l’ULN allo Screening (Visita 1).
    7. Valore di HbAlc =10% allo Screening (Visita 1).
    8. Livello di ormone tireostimolante >1,5 volte l’ULN allo Screening (Visita 1).
    9. Livello di creatinchinasi >3 volte l’ULN allo Screening (Visita 1).
    Si applicano altri criteri definiti da protocollo
    E.5 End points
    E.5.1Primary end point(s)
    EFFICACY
    1) the time from Randomization to the first confirmed occurrence of any component of the composite endpoint, including the following:
    - CV death;
    - Non-fatal MI;
    - Non-fatal stroke; or
    - Non-elective coronary revascularization.
    SAFETY
    2) AEs and events of special interest (ESIs);
    3) Vital signs;
    4) Electrocardiograms; and
    5) Clinical laboratory assessment
    EFFICACIA
    1) Tempo dalla randomizzazione al primo evento confermato tra gli endpoint compositi inclusi i seguenti:
    - morte cardiovascolare
    - infarto del miocardio non fatale
    - ictus non fatale, o
    - rivascolarizzazione coronarica non elettiva

    SICUREZZA
    2) Eventi avversi (AEs) e eventi di particolare interesse (ESIs)
    3) segni vitali
    4) elettrocardiogrammi, e
    5) Valutazioni cliniche di laboratorio
    E.5.1.1Timepoint(s) of evaluation of this end point
    1) Baseline to EOS
    2) V1 to EOT and EOS
    3) V1, V2, V4, V5, V6+Q6M, EOT
    4) Visit 2, EOT
    5) V1, V2, V4, V5, V6+Q6M, EOT
    1) Dalla baseline alla EOS
    2) Dalla V1 alla EOT e EOS
    3) V1, V2, V4, V5, V6+Q6M, EOT
    4) V2, EOT
    5) V1, V2, V4, V5, V6+Q6M, EOT
    E.5.2Secondary end point(s)
    The secondary efficacy endpoints, in hierarchical order, include the following:
    1) The time from Randomization until the first confirmed occurrence of a composite of CV death, non-fatal MI, or non-fatal stroke;
    2) The time from Randomization until the first confirmed occurrence of a composite of all-cause mortality, non-fatal MI, non-fatal stroke, or nonelective coronary revascularization;
    3) The time from Randomization until the first confirmed occurrence of CV death;
    4) The time from Randomization until the first confirmed occurrence of non-fatal MI;
    5) The time from Randomization until the first confirmed occurrence non-fatal stroke;
    6) The time from Randomization until the first confirmed occurrence of non-elective coronary revascularization;
    7) A total event analysis, defined as the number of CV death events, and first and subsequent/recurrent events of non-fatal MIs, non-fatal strokes, and non-elective coronary revascularization from Randomization until the EOS Visit;
    8) The time from Randomization until the first confirmed occurrence of NODM;
    9) Percent change in LDL-C from Baseline to Day 365 and to the EOT Visit;
    10) Percent change in non-HDL-C from Baseline to Day 365 and to the EOT Visit;
    11) Percent change in ApoB from Baseline to Day 365; and
    12) Percent change in HbA1c in participants with diabetes mellitus and HbA1c =7% at Baseline, from Baseline to Day 365 and to the EOT Visit
    Gli endpoints secondari sono in ordine gerarchico i seguenti:
    1) Il tempo dalla randomizzazione al primo evento confermato tra decesso CV, IM non fatale o ictus non fatale;
    2) Il tempo dalla randomizzazione al primo evento confermato di mortalità per tutte le cause, IM non fatale, ictus non fatale o rivascolarizzazione coronarica non elettiva;
    3) Il tempo dalla randomizzazione al primo evento confermato di decesso CV
    4) Il tempo dalla randomizzazione al primo evento confermato di IM non fatale
    5) Il tempo dalla randomizzazione al primo evento confermato di ictus non fatale;
    6) Il tempo dalla randomizzazione al primo evento confermato di rivascolarizzazione coronarica non elettiva
    7) Analisi degli eventi CV totali; definita come numero dei decessi CV, e primi e successivi IM non fatale, ictus non fatale e rivascolarizzazione coronarica non elettiva dalla randomizzazione alla EOS
    8) Il tempo dalla randomizzazione al primo evento confermato didiabete mellito di nuova insorgenza (NODM);
    9) variazione percentuale del colesterolo legato alle lipoproteine a bassa densità (LDL-C) dal giorno 365 alla EOT;
    10) variazione percentuale del colesterolo non legato alle lipoproteine ad alta densità (non-HDL-C)dal giorno 365 alla EOT;
    11) variazione percentuale dell’apolipoproteina B (ApoB);dal giorno 365 e
    12) variazione assoluta dell’emoglobina glicosilata (HbA1c) in partecipanti con diabete mellito e HbA1c =7% al basale dal giorno 365 alla EOT.
    E.5.2.1Timepoint(s) of evaluation of this end point
    1,2,3,4,5,6,8) Baseline to EOS
    7) EOS
    9,10,12) Baseline, Day 365/EOT
    11) Baseline to Day 365
    1,2,3,4,5,6,8) Dalla baseline alla EOS
    7) EOS
    9,10,12) Baseline, giorno 365/EOT
    11) Dalla baseline al giorno 365
    E.6 and E.7 Scope of the trial
    E.6Scope of the trial
    E.6.1Diagnosis No
    E.6.2Prophylaxis No
    E.6.3Therapy Yes
    E.6.4Safety Yes
    E.6.5Efficacy Yes
    E.6.6Pharmacokinetic Yes
    E.6.7Pharmacodynamic No
    E.6.8Bioequivalence No
    E.6.9Dose response No
    E.6.10Pharmacogenetic No
    E.6.11Pharmacogenomic No
    E.6.12Pharmacoeconomic No
    E.6.13Others No
    E.7Trial type and phase
    E.7.1Human pharmacology (Phase I) No
    E.7.1.1First administration to humans No
    E.7.1.2Bioequivalence study No
    E.7.1.3Other No
    E.7.1.3.1Other trial type description
    E.7.2Therapeutic exploratory (Phase II) No
    E.7.3Therapeutic confirmatory (Phase III) Yes
    E.7.4Therapeutic use (Phase IV) No
    E.8 Design of the trial
    E.8.1Controlled Yes
    E.8.1.1Randomised Yes
    E.8.1.2Open No
    E.8.1.3Single blind No
    E.8.1.4Double blind Yes
    E.8.1.5Parallel group No
    E.8.1.6Cross over No
    E.8.1.7Other No
    E.8.2 Comparator of controlled trial
    E.8.2.1Other medicinal product(s) No
    E.8.2.2Placebo Yes
    E.8.2.3Other No
    E.8.2.4Number of treatment arms in the trial2
    E.8.3 The trial involves single site in the Member State concerned No
    E.8.4 The trial involves multiple sites in the Member State concerned Yes
    E.8.4.1Number of sites anticipated in Member State concerned6
    E.8.5The trial involves multiple Member States Yes
    E.8.5.1Number of sites anticipated in the EEA200
    E.8.6 Trial involving sites outside the EEA
    E.8.6.1Trial being conducted both within and outside the EEA Yes
    E.8.6.2Trial being conducted completely outside of the EEA Information not present in EudraCT
    E.8.6.3If E.8.6.1 or E.8.6.2 are Yes, specify the regions in which trial sites are planned
    Australia
    Bulgaria
    Canada
    China
    Czechia
    Germany
    Hungary
    Israel
    Italy
    Japan
    Netherlands
    Poland
    Slovakia
    United Kingdom
    United States
    E.8.7Trial has a data monitoring committee Yes
    E.8.8 Definition of the end of the trial and justification where it is not the last visit of the last subject undergoing the trial
    LSLV (The DSMB will review 1 interim analysis during the study after approximately 671 events have been adjudicated, corresponding to approximately 70% of the planned total number of events for the study. After this interim analysis, the DSMB may recommend that the study continues, the study continues with sample size modifications, or the study is stopped for overwhelming efficacy, futility, or safety concerns)
    LSLV (Il DSMB rivedrà una analisi ad interim durante lo studio dopo circa 671 eventi, corrispondenti a circa il 70% di tutti gli eventi previsti nello studio. In seguito a questa analisi ad interim, il DSMB può raccomandare che lo studio continui, che continui con una modifica della numerosità o che lu studio sia stoppato per chiara efficacia, futilità o preocupazioni sulla sicurezza.
    E.8.9 Initial estimate of the duration of the trial
    E.8.9.1In the Member State concerned years4
    E.8.9.1In the Member State concerned months8
    E.8.9.1In the Member State concerned days0
    E.8.9.2In all countries concerned by the trial years5
    E.8.9.2In all countries concerned by the trial months1
    E.8.9.2In all countries concerned by the trial days0
    F. Population of Trial Subjects
    F.1 Age Range
    F.1.1Trial has subjects under 18 No
    F.1.1.1In Utero No
    F.1.1.2Preterm newborn infants (up to gestational age < 37 weeks) No
    F.1.1.3Newborns (0-27 days) No
    F.1.1.4Infants and toddlers (28 days-23 months) No
    F.1.1.5Children (2-11years) No
    F.1.1.6Adolescents (12-17 years) No
    F.1.2Adults (18-64 years) Yes
    F.1.2.1Number of subjects for this age range: 4050
    F.1.3Elderly (>=65 years) Yes
    F.1.3.1Number of subjects for this age range: 4950
    F.2 Gender
    F.2.1Female Yes
    F.2.2Male Yes
    F.3 Group of trial subjects
    F.3.1Healthy volunteers No
    F.3.2Patients Yes
    F.3.3Specific vulnerable populations Yes
    F.3.3.1Women of childbearing potential not using contraception No
    F.3.3.2Women of child-bearing potential using contraception Yes
    F.3.3.3Pregnant women No
    F.3.3.4Nursing women No
    F.3.3.5Emergency situation No
    F.3.3.6Subjects incapable of giving consent personally No
    F.3.3.7Others No
    F.4 Planned number of subjects to be included
    F.4.1In the member state295
    F.4.2 For a multinational trial
    F.4.2.1In the EEA 3700
    F.4.2.2In the whole clinical trial 9000
    F.5 Plans for treatment or care after the subject has ended the participation in the trial (if it is different from the expected normal treatment of that condition)
    standard of care
    standard of care
    G. Investigator Networks to be involved in the Trial
    G.4 Investigator Network to be involved in the Trial: 1
    G.4.1Name of Organisation Vascular Research Network (VRN)
    G.4.3.4Network Country Netherlands
    G.4 Investigator Network to be involved in the Trial: 2
    G.4.1Name of Organisation WCN
    G.4.3.4Network Country Netherlands
    N. Review by the Competent Authority or Ethics Committee in the country concerned
    N.Competent Authority Decision Authorised
    N.Date of Competent Authority Decision2022-04-12
    N.Ethics Committee Opinion of the trial applicationFavourable
    N.Ethics Committee Opinion: Reason(s) for unfavourable opinion
    N.Date of Ethics Committee Opinion2022-04-13
    P. End of Trial
    P.End of Trial StatusOngoing
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA